Blog
Log In
Contact us

Category: News

Categories
News

OMNY Health announces $17 Million Raise to Lead the Next Generation of Real-World Data-Driven Decision-Making and Collaboration Across Healthcare

OMNY Health compliantly connects a diverse network of healthcare stakeholders with research-ready data and insights, significantly reducing the burden of data acquisition and curation, and accelerating the time to decisions and action  

Atlanta, GA, November 30, 2022 /PRNewswire/ — OMNY, Inc. (d/b/a OMNY Health), a leader in compliant data and platform solutions for connecting healthcare stakeholders, today announced a $17 million Series B round led by Chicago Pacific Founders (CPF). Dr. Vance Vanier, MD, Co-Founder and Co-Managing Partner of CPF will join the OMNY Board of Directors. 

OMNY Health was created to enable any provider organization in the healthcare ecosystem to benefit from the value of Real-world data (RWD), while helping to reduce bias in data-driven decision-making across healthcare stakeholders. RWD and real-world evidence (RWE) play an essential and increasing role in health care decisions, but the current sources of administrative and payor data can create a biased, incomplete view of the care and associated outcomes. Similarly, clinical trials and other research studies often focus on patients receiving care at large academic centers or research sites that specialize in recruiting patients for studies, leaving patients from rural settings or those treated in community-based settings under-represented. OMNY Health answers these challenges with a proprietary unified national data layer, providing an efficient mechanism for Life Sciences companies to source research-ready data and insights from a broad mix of provider organizations across the country, with additional capability to compliantly connect with these provider organizations for follow-up research activities and collaborations. 

“Timely RWD and RWE have become the foundation for critical functions for countless healthcare companies. Unfortunately, teams today are stuck with data that doesn’t meet their needs, processes that waste time and money, and few options for acting on the insights generated,” said Mitesh Rao, MD, Founder and CEO of OMNY Health. “This situation is no longer tenable in today’s fast-paced data-driven environment. Healthcare stakeholders shouldn’t be forced to make decisions based on inadequate information. This new investment will fuel our growth as we continue to meet the accelerating demand for more seamless data-driven decision-making in healthcare and opportunities to better engage with patients and providers through the common language of data.” 

OMNY’s proprietary DaaS and SaaS solutions spearhead the evolutionary transition to dynamic data procurement and insight generation by seamlessly normalizing data from disparate electronic health record systems across diverse sets of provider sizes and types. As a result, researchers can gain the flexibility they need to acquire fit-for-purpose data that can scale up or down based on their needs. This allows them to significantly reduce data acquisition costs and alleviate the stress of managing multiple data vendors and the compliance activities associated with provider relationships. Today, OMNY’s dynamic data ecosystem represents more than 56 million individuals from health systems and specialty provider networks across 42 states, with many more scheduled to join in 2023. More than a dozen Life Sciences companies are leveraging the OMNY Platform and data network to meet their research and analytic needs since the platform commercially launched in May 2021.  

“OMNY’s demonstrated capability of enabling providers and Life Sciences companies to create partnerships around real-world data will transform patient care. We are thrilled to have the opportunity to participate in the next stage of OMNY’s journey,” said Vance Vanier, M.D. Co-founder and Co-Managing Partner of CPF. 

About OMNY Health

The OMNY Health ecosystem is the premiere real-world data layer, securely connecting researchers and healthcare providers through a common language of deidentified data. Serving as a key resource and central intermediary, OMNY Health revolutionizes the potential for providers and life sciences organizations to align goals across the healthcare industry, forging transformative data relationships and fueling innovation where patients need it the most. For more information on the OMNY Health network, please visit www.marketing-dev.omnyhealth.com.  

About Chicago Pacific Founders 

Based in Chicago and San Francisco, Chicago Pacific Founders (“CPF”) is a leading strategic private equity firm focused on investing in growth companies within value-based care, healthcare services, AI and tech enabled services, and caring for aging populations. CPF believes that the most significant societal impact and investment returns from healthcare for the next decade will be generated by investment in delivery model innovation. CPF’s leadership team is comprised of former healthcare founders, senior executives, and investment professionals with a passion and track record of building healthcare businesses. For more information, please visit www.cpfounders.com. 

MEDIA INQUIRIES:  please contact Stacey Long, stacey@omnyhealth.com

View full press release

Categories
News

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI

Sensyne and OMNY will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines

The Teaming Agreement allows OMNY to engage Sensyne’s data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health’s 22 million de-identified patient records

Dover, DE and Atlanta, GA. Oxford, U.K. October 13, 2021: Sensyne Health plc (LSE: SENS) (“Sensyne”), the ethical Clinical AI company, and OMNY Health (“OMNY”), a leading US-based real world data company, today announced a strategic teaming relationship.

The arrangement establishes a nimble framework under which Sensyne can subscribe to data offerings via the OMNY Health Platform, which features more than 22 million de-identified patient records across broad therapeutic areas in support of Sensyne’s data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research.  By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies—and their health system partners—will have more opportunities to support important life sciences research.

The OMNY data network complements Sensyne’s existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK’s National Health Service (NHS) trusts. With representation from  over 50,000 providers across 40 states, the OMNY Health Platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations.  Sensyne will now have a new avenue to access data from OMNY’s catalog of over 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the possible combined total of de-identified patient data available for collaborative research to over 44m patients.  

Derek Baird, President, North America, Sensyne Health said:

“This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way.  We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together.”

Mitesh Rao, MD, CEO, OMNY Health said:

“OMNY Health embraces the opportunity to work with Sensyne Health’s world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform.  We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry. This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we’ve assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients.”
Sensyne is working with life science partners on different types of research projects across multiple disease areas. The actionable insights from OMNY’s longitudinal patient data sets will help them with synthetic control arms, patient stratification, patient identification and selection, plus important late-phase clinical trial design, commercialisation, and health economic pricing decisions.

For more information email: lifesciences@omnyhealth.com.

Categories
News

OMNY Health Launches Massive Integrated Dermatology Data Repository and Research Network to Advance Life-Changing Innovations for Patients Suffering from Skin-Related Conditions

ATLANTA, June 23, 2021 /PRNewswire/ — OMNY Health (OMNY Inc.) is pleased to announce it has partnered with the nation’s leading community-based dermatology practices to create a first-of-a-kind integrated, normalized, de-identified electronic health record (EHR) data repository for dermatological research.

The assembled longitudinal data represents care delivered over the past five years by over 1,000 dermatologic providers in more than 30 states, across more than 7.5 million unique patients. OMNY Health works with providers to integrate and standardize their siloed disparate EHR data, enabling the delivery of de-identified data into research-ready subscriptions for Life Sciences organizations, while also delivering insights based on the normalized data back to the data contributors.

At the core of the OMNY Health platform is de-identified, normalized EHR data, further enhanced with tokens that support linkages to data derived from administrative claims, registries and other data resources, while maintaining patient anonymity. OMNY Health leverages natural language processing (NLP) technology to analyze unstructured data to derive insights often buried in clinician notes, such as adverse drug events, social determinants of health, and reasons for therapy changes.

“We are excited to partner with these forward-thinking dermatology providers to launch OMNY Health’s first suite of specialty databases. As the number of specialty treatment options expands, OMNY Health provides an ideal platform for delivering scalable data solutions to life sciences companies needing to understand the care delivered by the diverse mix of providers treating patients along their care journey. Data available on the platform provides the information needed to better understand the patient and provider landscape, design and identify eligible patients for trials, monitor the impact of launch of new therapies in the real-world setting, and evaluate safety and effectiveness of those therapies”, said Dr. Mitesh Rao, CEO at OMNY Health.

Investment in dermatology has experienced double-digit growth over the past several years and is expected to continue to grow, particularly for the conditions falling at the intersection of inflammatory and autoimmune skin disorders, such as alopecia areata, psoriasis, and atopic dermatitis. “We can now address the retrospective and prospective data and analytic needs of life sciences organizations working on treatments for some of the rarest dermatologic conditions, such as epidermolysis bullosa and generalized pustular psoriasis, to common conditions such as acne, and everything in between,” said Stacey Long, Chief Strategy Officer, who oversees OMNY Health’s product and data science teams.

“Advanced Dermatology and Cosmetic Surgery, the nation’s premier dermatology practice, values our partnership with OMNY. As we actively explore cutting edge therapeutics and leverage our robust data set to find ways to best serve our patients and the dermatology community, a collaboration with an advanced partner, like OMNY is crucial to our long-term success.” Allison W. Lynch, Chief Operating Officer, Clinical Research

“We are excited to partner with OMNY Health in looking at real world data. It’s an invaluable resource that creates improved patient outcomes, quality metrics, cost efficiencies, and tools for evaluating best practice opportunities. It also allows for prospective research to evaluate new ideas, therapies, and measurement tools that can assist in making better decisions for patients, physicians, payers, and the industry,” said Dr. Mark Jackson, Clinical Professor of Dermatology, University of Louisville and Director of Medical/Clinical Research, Forefront Dermatology.

Dr. Jackson will join Lawrence Rasouliyan, OMNY Health’s Head of Biostatistics and Data Science, on June 24, for a webinar discussion on the vital role of physicians in supporting real-world evidence generation in dermatology and the transformative opportunity for patients, providers, and life sciences organizations. Register at https://marketing-dev.omnyhealth.com/events-webinars/register-for-webinar-real-world-data-in-dermatology-why-it-matters/

About OMNY Health

OMNY Health connects patients, providers, and life sciences companies through data and insights to transform healthcare delivery, improve clinical outcomes, and address patient’s unmet needs. For more information, go to www.marketing-dev.omnyhealth.com or email: lifesciences@omnyhealth.com.

View full press release

Categories
News

OMNY Health Launches Platform to Accelerate Life-Changing Innovations through Data-Driven Insights

Connects data from hospitals, health systems, specialty medical groups with life sciences researchers 

ATLANTA, May 6, 2021 /PRNewswire/ — OMNY Health (OMNY Inc.) today announced commercial availability of the OMNY Health Platform™,  a healthcare data-sharing solution that accelerates innovation by connecting the healthcare ecosystem with opportunities to connect anonymized data with researchers from life sciences organizations. Platform clients can use this data to develop new therapies, enhance treatment availability, and measure effectiveness.

The use of anonymized real-world treatment data to support life sciences companies’ decision-making across healthcare is not new. It is, however, often done without the direct involvement of healthcare providers — the originators of the information. The OMNY Health Platform offers provider organizations of all sizes the ability to participate in data-sharing partnerships with life sciences organizations to support research activities in an efficient and compliant manner.

“As a healthcare executive focused on patient safety and quality, I was often frustrated with our inability to efficiently partner with life sciences companies to help address patients’ treatment challenges and understand unmet needs,” said Mitesh Rao MD, CEO and Founder of OMNY Health. “OMNY Health provides a trusted, compliant solution for patients and providers to build transparent and secure data-driven relationships at scale and with minimal effort.”

The OMNY Health Platform centers on de-identified, normalized electronic health record data, enhanced with tokens that support links across the data ecosystem, all while preserving patient anonymity.  A diverse set of hospitals, health systems, and specialty provider organizations have already agreed to join the network, representing care delivered in more than 39 states and more than 10 million patient lives.

The platform contains more than 100 pre-packaged searchable and downloadable data offerings, aligned to strategic therapeutic areas, drug classes, and procedure groups.  The direct-from-source data on the platform cover both inpatient and outpatient care and all payer types. OMNY can also provide custom data cuts and analyses for life sciences researchers.  Insights from these data can help better understand unmet patient needs, design more efficient clinical trials, and inform strategies to address challenges in access to care.

The number of organizations opting to participate on the data sharing platform is rapidly growing, as are the types of data being made available.

“We focused on creating a flexible, scalable architecture that supports the diverse set of data needed by life sciences organizations to meet multiple use cases across the value chain, and one that could easily integrate into their workflows,” said Sean O’Brien, co-founder and Chief Technology Officer at OMNY.  “Time and budget constraints can hinder life sciences companies from getting the information needed for faster, more-effective decision-making.  Our platform specifically addresses these challenges.”

Solution demonstrations and studies showcasing the diverse data available via the OMNY Health Platform are scheduled to be presented during a variety of events this summer, including ISPOR, DIA, and ICPE.

About OMNY Health OMNY Health connects patients, providers, and life sciences companies through data and insights to accelerate life-changing innovation.  Our easy-to-use, secure platform enables life sciences organizations to engage in collaborative data and research partnerships efficiently, compliantly, and at scale.

The team at OMNY Health imagines a future of patient-centered and evidence-based care. We’ll achieve that mission through a seamless workflow of analysis-to-insight-to-decision-making based on a connected ecosystem of healthcare data and collaboration across the healthcare ecosystem.   

For more information visit www.marketing-dev.omnyhealth.com or e-mail:lifesciences@omnyhealth.com.

View full press release

Categories
News

OMNY Health™ Debuts at Health 2.0 Launch!

OMNY Health took home the audience vote and the grand prize at Health 2.0

Eight new digital companies took the stage at Health 2.0’s Annual Conference in San Francisco on September 20, 2019 to give the first public demos of their products for the show’s annual “Launch!” event.

OMNY Health™, which aims to disrupt data sharing and give providers more control over the data they sell, took home the audience vote and the $5,000 grand prize. All eight companies boasted interesting ideas and impressive accomplishments so far, and we are honored to be in their company.

To read more, please visit mobihealthnews.com.

Categories
News

HealthTech Arkansas Names Six Startups to Cohort

HealthTech Arkansas named six startup companies, including OMNY Health™, for its second cohort on August 6th, 2019. HealthTech is an accelerator program for healthcare technology startup firms that will collaborate with nine healthcare providers in Arkansas.

The six companies were selected from hundreds of applicants across 18 different countries and are headquartered in innovation capitals like San Francisco, New York, Boston, San Diego, and Seattle. According to HealthTech leaders, the six companies already have 177 full-time employees and have raised over $90 million of external capital after forming the companies.

To read more, please visit talkbusiness.net.

Categories
News

BTG and OMNY Health™ Partner to Improve Treatment

For the estimated 7,000 individuals bitten by rattlesnakes, copperheads, and cottonmouths in the U.S. each year, “time is tissue” and timely treatment is critical. Patients that are not quickly and appropriately treated are at risk of skin and tissue damage, limb function disability or loss, neurotoxic effects, dangerous internal bleeding, and systemic injury to the heart, stomach, and other organs. This makes it important to understand and manage antivenom stock levels.

Using the OMNY Health™ platform, near real-time data about CroFab® stock levels at participating healthcare institutions will be captured and securely shared with BTG and the Rocky Mountain Poison & Drug Center (RMPDC), and in time will expand to additional healthcare providers and poison control centers.

For more details, please read the press release.